Sofiva Genomics Co.,Ltd. provides genetic testing services in Taiwan and internationally. More Details
Flawless balance sheet with questionable track record.
Share Price & News
How has Sofiva GenomicsLtd's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6615 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 6615's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 6615 underperformed the TW Healthcare industry which returned 11.9% over the past year.
Return vs Market: 6615 underperformed the TW Market which returned 48.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Sofiva GenomicsLtd's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StSome Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital
3 months ago | Simply Wall StEstimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)
3 months ago | Simply Wall StSofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend
Is Sofiva GenomicsLtd undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 6615 (NT$53) is trading above our estimate of fair value (NT$51.67)
Significantly Below Fair Value: 6615 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 6615 is poor value based on its PE Ratio (34x) compared to the TW Healthcare industry average (16.8x).
PE vs Market: 6615 is poor value based on its PE Ratio (34x) compared to the TW market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6615's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6615 is overvalued based on its PB Ratio (2.1x) compared to the TW Healthcare industry average (1.9x).
How is Sofiva GenomicsLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sofiva GenomicsLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Sofiva GenomicsLtd performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6615 has high quality earnings.
Growing Profit Margin: 6615's current net profit margins (6.7%) are lower than last year (11.7%).
Past Earnings Growth Analysis
Earnings Trend: 6615's earnings have grown by 3.7% per year over the past 5 years.
Accelerating Growth: 6615's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6615 had negative earnings growth (-44.1%) over the past year, making it difficult to compare to the Healthcare industry average (-2.6%).
Return on Equity
High ROE: 6615's Return on Equity (6.1%) is considered low.
How is Sofiva GenomicsLtd's financial position?
Financial Position Analysis
Short Term Liabilities: 6615's short term assets (NT$338.7M) exceed its short term liabilities (NT$126.7M).
Long Term Liabilities: 6615's short term assets (NT$338.7M) exceed its long term liabilities (NT$85.2M).
Debt to Equity History and Analysis
Debt Level: 6615's debt to equity ratio (0.1%) is considered satisfactory.
Reducing Debt: 6615's debt to equity ratio has reduced from 15.3% to 0.1% over the past 5 years.
Debt Coverage: 6615's debt is well covered by operating cash flow (10393.9%).
Interest Coverage: 6615's interest payments on its debt are well covered by EBIT (13.5x coverage).
What is Sofiva GenomicsLtd current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 6615's dividend (2.64%) is higher than the bottom 25% of dividend payers in the TW market (2.04%).
High Dividend: 6615's dividend (2.64%) is low compared to the top 25% of dividend payers in the TW market (5.01%).
Stability and Growth of Payments
Stable Dividend: 6615 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 6615 has only been paying a dividend for 4 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (89.8%), 6615's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Sofiva GenomicsLtd has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sofiva Genomics Co.,Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Sofiva Genomics Co.,Ltd.
- Ticker: 6615
- Exchange: TPEX
- Founded: 2012
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: NT$1.127b
- Shares outstanding: 21.26m
- Website: https://www.sofivagenomics.com.tw
Number of Employees
- Sofiva Genomics Co.,Ltd.
- No. 27, Baoqing Road
- Zhongzheng District
Sofiva Genomics Co.,Ltd. provides genetic testing services in Taiwan and internationally. The company offers prenatal services, including thalassemia carrier screening; tests for microdeletion syndromes an...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/17 23:02|
|End of Day Share Price||2021/06/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.